biotech stocks declined for the second straight week amid a broader market pullback along with earnings news from small and microcap companies and presentations at multiple conferences among the biggest news of the week is johnson  johnsons nyse jnj announcement regarding the spinoff of its consumer health business eton pharmaceuticals inc nasdaq etons topiramate oral solution received approval from the food and drug administration for certain types of seizures in patients two years of age and older and as a preventative treatment of migraine in patients 12 years of age and older azurity pharma the sponsor of the new drug application had purchased topiramate along with two other neurology candidates from eton eton is eligible to receive a 5 million milestone payment and also royalties on sales oncorus inc nasdaq oncr was among the biggest decliners of the week following the companys presentation of earlystage data for a cancer immunotherapy candidate at the society for immunotherapy of cancer conference here are the key upcoming catalysts that a biotech investor should focus on in the unfolding week society for immunotherapy of cancer nov 1014 hybrid event to be held in washington dc and to be available virtually american association for the study of liver diseases aasld the liver meeting 2021 nov 1215 virtual meeting the american society for dermatologic surgery or asds virtual annual meeting nov 1921 the fda is scheduled to rule on biomarin pharmaceutical incs nasdaq bmrn nda for vosoritide an investigational once daily injection for treating children with achondroplasia the most common form of disproportionate short stature in humans the pdufa date is set for saturday nov 20 kezar life sciences inc nasdaq kzr interim phase 2 data for kzr616 in lupus and data for kzr261 monday at 430 pm proqr therapeutics nv nasdaq prqr updated data from the phase 12 insight extension study of sepofarsen in leber congenital amaurosis type 10 thursday plus therapeutics inc nasdaq pstv phase 1 data for rhenium186 nanoliposome in glioblastoma multiforme thursday cymabay therapeutics inc nasdaq cbay phase 3 data for seladelpar in patients with primary biliary cholangitis milestone pharmaceuticals inc nasdaq mist new analyses on the impact of etripamil on heart rate in patients with paroxysmal supraventricular tachycardia sunday phasebio pharmaceuticals inc nasdaq phas prespecified interim analysis of pivotal reverseit phase 3 trial of bentracimab for the reversal of the antiplatelet effects of ticagrelor in patients who present with uncontrolled major bleeding or who require surgery or invasive procedure monday amarin corporation plc nasdaq amrn main results of the phase 3 prepareit2 study of vascepa vs placebo in outpatients with covid19 monday vaccitech plc nasdaq vacc safety and immunogenicity data from the leadin portion of the phase 12a clinical trial of vtp200 candel therapeutics inc nasdaq cadl initial safety data on can2409 in combination with bristolmyers squibb companys nyse bmy opdivo from a phase 1 clinical trial in highgrade glioma chimerix inc nasdaq cmrx clinical efficacy of onc201 in recurrent h3 k27mmutant diffuse midline glioma patients saturday dermata therapeutics inc nasdaq drma efficacy and safety results for its phase 1b proof of concept study evaluating a single application of dmt410 to treat multiple aesthetic skin conditions friday urogen pharma ltd nasdaq urgn monday before the market open  milestone scientific inc nyse mlss monday before the market open  trevena inc nasdaq trvn monday before the market open  kala pharmaceuticals inc nasdaq kala monday before the market open  vascular biogenics ltd nasdaq vblt monday before the market open  dariohealth corp nasdaq drio monday before the market open  gamida cell ltd nasdaq gmda monday before the market open  protalix biotherapeutics inc nyse plx monday before the market open  acelrx pharmaceuticals inc nasdaq acrx monday before the market open  athersys inc nasdaq athx monday before the market open  aytu biopharma inc nasdaq aytu monday after the close  pulse biosciences inc nasdaq plse monday after the close  invo bioscience inc nasdaq invo monday after the close  evofem biosciences inc nasdaq evfm monday after the close  biocept inc nasdaq bioc monday after the close  immucell corporation nasdaq iccc monday after the close  eton pharmaceuticals inc nasdaq eton monday after the close  syndax pharmaceuticals inc nasdaq sndx monday after the close  optinose inc nasdaq optn monday after the close  osmotica pharmaceuticals plc nasdaq osmt monday after the close  mirum pharmaceuticals inc nasdaq mirm monday after the close  ra medical systems inc nyse rmed monday after the close  rockwell automation inc nyse rok monday after the close  precipio inc nasdaq prpo monday after the close  tff pharmaceuticals inc nasdaq tffp monday after the close  mediwound ltd nasdaq mdwd tuesday after the close  pavmed inc nasdaq pavm tuesday after the close  edap tms sa nasdaq edap wednesday after the close context therapeutics inc nasdaq cntx  minerva surgical inc nasdaq utrs  xilio therapeutics inc nasdaq xlo  ventyx biosciences inc nasdaq vtyx